BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InNexus Inc. Closes Private Placement For $940,500


10/19/2005 5:12:06 PM

VANCOUVER, Nov. 5 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. is pleased to announce that it has closed 2,090,000 shares of its previously announced non-brokered private placement at $0.45 per share for gross proceeds of $940,500. These shares will be subject to a hold period expiring on March 5, 2005.

InNexus has paid finders fees of $71,460 with respect to this placement. In addition, InNexus has granted Williams de Broe PLC of London a non- transferable option to acquire 193,000 common shares of the Company at a price of $0.45 per share, exercisable for a period of two years from the closing of the placement. One of the longest established brokerage firms in the City of London, Williams de Broe is a subsidiary of the ING Group of Holland and a Member of the London Stock Exchange.

The net proceeds of this placement will be applied to general working capital.

About InNexus

InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus will develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: http://www.innexusbiotech.com/

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

On behalf of the Board of Directors of InNexus Biotechnology, Inc. "ALTON C. MORGAN" Dr. A. Charles Morgan President The TSX Venture Exchange has neither approved nor disapproved of the information contained herein. Contacts -------- InNexus Contact: Business Development: Investor Relations: Telephone (toll-free): 1-877-990-8382 Toll-free: 1-866-990-8382 or Fax: (425) 696-0068 1-888-271-0788 Email: business@innexusbiotech.cominvestor@innexusbiotech.com

InNexus Biotechnology, Inc.

CONTACT: InNexus Contact: Business Development -Telephone (toll-free): 1-877-990-8382, Fax: (425) 696-0068,Email: business@innexusbiotech.com; Investor Relations - Toll-free:1-866-990-8382 or 1-888-271-0788, investor@innexusbiotech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES